These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 25943074)

  • 1. Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage.
    Campos NG; Castle PE; Wright TC; Kim JJ
    Int J Cancer; 2015 Nov; 137(9):2208-19. PubMed ID: 25943074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. To expand coverage, or increase frequency: Quantifying the tradeoffs between equity and efficiency facing cervical cancer screening programs in low-resource settings.
    Campos NG; Tsu V; Jeronimo J; Mvundura M; Lee K; Kim JJ
    Int J Cancer; 2017 Mar; 140(6):1293-1305. PubMed ID: 27925175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the value of point-of-care HPV testing in three low- and middle-income countries: a modeling study.
    Campos NG; Tsu V; Jeronimo J; Mvundura M; Kim JJ
    BMC Cancer; 2017 Nov; 17(1):791. PubMed ID: 29178896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of an HPV self-collection campaign in Uganda: comparing models for delivery of cervical cancer screening in a low-income setting.
    Campos NG; Tsu V; Jeronimo J; Njama-Meya D; Mvundura M; Kim JJ
    Health Policy Plan; 2017 Sep; 32(7):956-968. PubMed ID: 28369405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of increasing cervical cancer screening coverage in the Middle East: An example from Lebanon.
    Sharma M; Seoud M; Kim JJ
    Vaccine; 2017 Jan; 35(4):564-569. PubMed ID: 28017434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health impact of delayed implementation of cervical cancer screening programs in India: A modeling analysis.
    Campos NG; Tsu V; Jeronimo J; Regan C; Resch S; Clark A; Sy S; Kim JJ
    Int J Cancer; 2019 Feb; 144(4):687-696. PubMed ID: 30132850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study.
    Shi JF; Canfell K; Lew JB; Zhao FH; Legood R; Ning Y; Simonella L; Ma L; Kang YJ; Zhang YZ; Smith MA; Chen JF; Feng XX; Qiao YL
    BMC Cancer; 2011 Jun; 11():239. PubMed ID: 21668946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador.
    Campos NG; Maza M; Alfaro K; Gage JC; Castle PE; Felix JC; Cremer ML; Kim JJ
    Int J Cancer; 2015 Aug; 137(4):893-902. PubMed ID: 25639903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of human papilloma virus-DNA test verses colposcopy as secondary cervical cancer screening test to triage screen positive women on primary screening by visual inspection with 5% acetic acid.
    Pimple S; Shastri SS
    Indian J Cancer; 2014; 51(2):117-23. PubMed ID: 25104191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uptake of community-based, self-collected HPV testing vs. visual inspection with acetic acid for cervical cancer screening in Kampala, Uganda: preliminary results of a randomised controlled trial.
    Moses E; Pedersen HN; Mitchell SM; Sekikubo M; Mwesigwa D; Singer J; Biryabarema C; Byamugisha JK; Money DM; Ogilvie GS
    Trop Med Int Health; 2015 Oct; 20(10):1355-67. PubMed ID: 26031572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of novel, lower cost molecular human papillomavirus-based tests for cervical cancer screening in rural china.
    Valdez M; Jeronimo J; Bansil P; Qiao YL; Zhao FH; Chen W; Zhang X; Kang LN; Paul P; Bai P; Peck R; Li J; Chen F; Stoler MH; Castle PE
    Int J Cancer; 2016 Mar; 138(6):1453-61. PubMed ID: 26421807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
    Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
    Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study on the value assessment of various screening programs regarding cervical cancer screening strategy in the rural areas of China].
    Li LY; Qiao ZQ; Zhang MF; Yang JP; Bao YP; An YT; Lei J; Xiong NH; Yu XH; Zhang X; Pan QJ; Qiao YL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Oct; 28(10):964-7. PubMed ID: 18399140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for cervical cancer among HIV-positive and HIV-negative women in Cameroon using simultaneous co-testing with careHPV DNA testing and visual inspection enhanced by digital cervicography: Findings of initial screening and one-year follow-up.
    Cholli P; Bradford L; Manga S; Nulah K; Kiyang E; Manjuh F; DeGregorio G; Ogembo RK; Orock E; Liu Y; Wamai RG; Sheldon LK; Gona PN; Sando Z; Welty T; Welty E; Ogembo JG
    Gynecol Oncol; 2018 Jan; 148(1):118-125. PubMed ID: 29153541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Community-based HPV self-collection versus visual inspection with acetic acid in Uganda: a cost-effectiveness analysis of the ASPIRE trial.
    Mezei AK; Pedersen HN; Sy S; Regan C; Mitchell-Foster SM; Byamugisha J; Sekikubo M; Armstrong H; Rawat A; Singer J; Ogilvie GS; Kim JJ; Campos NG
    BMJ Open; 2018 Jun; 8(6):e020484. PubMed ID: 29895648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing high risk HPV-based primary screening for cervical cancer in low- and middle-income countries: opportunities and challenges.
    Pimple SA; Mishra GA
    Minerva Ginecol; 2019 Oct; 71(5):365-371. PubMed ID: 31698891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of alternative screening strategies for the detection of cervical cancer among women in rural areas of Western Kenya.
    Lobin C; Orang'o EO; Were E; Muthoka K; Singh K; De Allegri M; Obermann K; von Knebel Doeberitz M; Bussmann H
    Int J Cancer; 2024 Oct; 155(7):1257-1267. PubMed ID: 38801325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The road to cervical cancer elimination in Malaysia: Evaluation of the impact and cost-effectiveness of human papillomavirus screening with self-collection and digital registry support.
    Keane A; Ng CW; Simms KT; Nguyen D; Woo YL; Saville M; Canfell K
    Int J Cancer; 2021 Dec; 149(12):1997-2009. PubMed ID: 34363620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementing the 3T-approach for cervical cancer screening in Cameroon: Preliminary results on program performance.
    Levy J; de Preux M; Kenfack B; Sormani J; Catarino R; Tincho EF; Frund C; Fouogue JT; Vassilakos P; Petignat P
    Cancer Med; 2020 Oct; 9(19):7293-7300. PubMed ID: 32757469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
    Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.